Rich Law
@drrichjlaw.bsky.social
Chief Business Officer of Haya Therapeutics! (formerly Exscientia/Recursion CBO), computational chemist by training (Oxford, UCSD, LLNL & Evotec), bike racer, ex-Oxford rower & LFC fan! #YNWA.
Pinned
Rich Law
@drrichjlaw.bsky.social
· Apr 25
Reprogramming the software of the cell to fight disease
HAYA Therapeutics is using its unparalleled regulatory genome atlas and innovative proprietary platform to identify novel long non-coding RNAs and develop drug candidates that return diseased cells ba...
www.nature.com
Haya Therapeutics
www.nature.com/articles/d43...
www.nature.com/articles/d43...
NHS & NICE double down on their decision to not approve Eli Lilly’s donanemab and Biogen/Eisai’s lecanemab due to lack of cost effectieve efficacy; www.ddw-online.com/nice-rejects...
NICE rejects Alzheimer’s drugs for lack of cost-effectiveness - Drug Discovery World (DDW)
The UK National Institute for Health and Care Excellence (NICE) has reached its final decision on two Alzheimer’s treatments, denying their use on the NHS due to the therapies not providing “good valu...
www.ddw-online.com
June 25, 2025 at 8:54 AM
NHS & NICE double down on their decision to not approve Eli Lilly’s donanemab and Biogen/Eisai’s lecanemab due to lack of cost effectieve efficacy; www.ddw-online.com/nice-rejects...
BioNTech to acquire CureVac $CVAC in all-stock deal valued at $1.25B (although they have $500M in cash!) - 30% premium on close but only ~10% of it's MC from 4 yrs ago. endpoints.news/biontech-to-...
BioNTech to acquire CureVac in all-stock deal valued at $1.25B
BioNTech plans to buy mRNA-based cancer immunotherapy and infectious disease vaccine company CureVac in an all-stock deal, the companies said Thursday.
endpoints.news
June 12, 2025 at 12:02 PM
BioNTech to acquire CureVac $CVAC in all-stock deal valued at $1.25B (although they have $500M in cash!) - 30% premium on close but only ~10% of it's MC from 4 yrs ago. endpoints.news/biontech-to-...
BioNTech to acquire CureVac $CVAC in all-stock deal valued at $1.25B (although they have $500M in cash!) - 30% premium on close but only ~10% of it's MC from 4 yrs ago. endpoints.news/biontech-to-...
BioNTech to acquire CureVac in all-stock deal valued at $1.25B
BioNTech plans to buy mRNA-based cancer immunotherapy and infectious disease vaccine company CureVac in an all-stock deal, the companies said Thursday.
endpoints.news
June 12, 2025 at 11:55 AM
BioNTech to acquire CureVac $CVAC in all-stock deal valued at $1.25B (although they have $500M in cash!) - 30% premium on close but only ~10% of it's MC from 4 yrs ago. endpoints.news/biontech-to-...
Schrödinger says early MALT1 data could lay 'great foundation' for combos. Indeed the future of oncology is very much about combination therapies & in many complex biological settings, we need to get over the need for single agent efficacy for everything. endpoints.news/eha25-schrod...
Schrödinger says early MALT1 data could lay 'great foundation' for combos
Schrödinger said its experimental MALT1 inhibitor showed early signs of safety and efficacy in an ongoing Phase 1 trial.
endpoints.news
June 12, 2025 at 11:46 AM
Schrödinger says early MALT1 data could lay 'great foundation' for combos. Indeed the future of oncology is very much about combination therapies & in many complex biological settings, we need to get over the need for single agent efficacy for everything. endpoints.news/eha25-schrod...
Sofinnova Partners Collaborates With NVIDIA to Accelerate European Life Sciences Startups
www.businesswire.com/news/home/20...
www.businesswire.com/news/home/20...
Sofinnova Partners Collaborates With NVIDIA to Accelerate European Life Sciences Startups
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced a collaboration wi...
www.businesswire.com
June 11, 2025 at 2:56 PM
Sofinnova Partners Collaborates With NVIDIA to Accelerate European Life Sciences Startups
www.businesswire.com/news/home/20...
www.businesswire.com/news/home/20...
Sanofi to buy Blueprint Medicines in deal worth more than $9 billion (roughly 30% premium on Friday close). $BPMC $XBI
www.statnews.com/2025/06/02/s...
www.statnews.com/2025/06/02/s...
Sanofi to buy Blueprint Medicines in deal worth more than $9 billion
Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, expanding its immunology pipeline
www.statnews.com
June 2, 2025 at 10:55 AM
Sanofi to buy Blueprint Medicines in deal worth more than $9 billion (roughly 30% premium on Friday close). $BPMC $XBI
www.statnews.com/2025/06/02/s...
www.statnews.com/2025/06/02/s...
Bristol Myers $BMY bets $1.5B on BioNTech's PD-L1xVEGF from Chinese Biotheus partner.
endpts.com/bristol-myer...
endpts.com/bristol-myer...
Bristol Myers bets $1.5B on BioNTech's PD-L1xVEGF from Biotheus
BioNTech bought out its China-based biotech partner Biotheus for $800 million upfront in November. Now, the German drugmaker is set to receive $1.5 billion upfront from Bristol Myers Squibb to co-deve...
endpts.com
June 2, 2025 at 10:54 AM
Bristol Myers $BMY bets $1.5B on BioNTech's PD-L1xVEGF from Chinese Biotheus partner.
endpts.com/bristol-myer...
endpts.com/bristol-myer...
Reposted by Rich Law
Sanofi to acquire Blueprint Medicines $BPMC for $9.1 billion
#immunology #deal #pharma #biotech
www.sanofi.com/en/media-roo...
#immunology #deal #pharma #biotech
www.sanofi.com/en/media-roo...
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and...
www.sanofi.com
June 2, 2025 at 6:07 AM
Sanofi to acquire Blueprint Medicines $BPMC for $9.1 billion
#immunology #deal #pharma #biotech
www.sanofi.com/en/media-roo...
#immunology #deal #pharma #biotech
www.sanofi.com/en/media-roo...
Detailed doc released showing how NIH’s discretionary budget will be slashed to $27.5 billion, an $18 billion or nearly 40% reduction. It also details plans to consolidate the agency’s 27 institutes & centers into just 8. www.statnews.com/2025/05/30/n...
New HHS document details deep NIH cuts as part of Trump budget request
Budget documents for Congress provide the most detailed look yet at how the Trump Administration hopes to reshape the National Institutes of Health.
www.statnews.com
May 31, 2025 at 6:51 AM
Detailed doc released showing how NIH’s discretionary budget will be slashed to $27.5 billion, an $18 billion or nearly 40% reduction. It also details plans to consolidate the agency’s 27 institutes & centers into just 8. www.statnews.com/2025/05/30/n...
"About a quarter of the approximately 13,600 drug-target pairs in the current preclinical and clinical R&D pipeline are concentrated around just 38 unique biological targets." - LEK. This is astonishing & a huge misappropriation of risk by investors.
www.lek.com/insights/hea...
www.lek.com/insights/hea...
Is Biopharma Doing Enough to Advance Novel Targets? | L.E.K. Consulting
Is Biopharma Doing Enough to Advance Novel Targets?
www.lek.com
May 30, 2025 at 10:21 AM
"About a quarter of the approximately 13,600 drug-target pairs in the current preclinical and clinical R&D pipeline are concentrated around just 38 unique biological targets." - LEK. This is astonishing & a huge misappropriation of risk by investors.
www.lek.com/insights/hea...
www.lek.com/insights/hea...
Great interview (read) with @HAYA_lncRNA CEO SAmir Ounzain as he talks about the unique science of Haya & executing as a first-in-biology biotech. pharmaboardroom.com/interviews/s...
Samir Ounzain – CEO & Scientific Co-Founder, HAYA Therapeutics
What if the key to treating chronic and age-related diseases has been hidden in plain sight, within…
pharmaboardroom.com
May 29, 2025 at 4:44 PM
Great interview (read) with @HAYA_lncRNA CEO SAmir Ounzain as he talks about the unique science of Haya & executing as a first-in-biology biotech. pharmaboardroom.com/interviews/s...
Investors pump $130M into protein degrader startup GlycoEra
endpts.com/investors-pu...
endpts.com/investors-pu...
Investors pump $130M into protein degrader startup GlycoEra
Protein degrader shop GlycoEra, spun out of vaccines company LimmaTech in 2021, has corralled $130 million in Series B funding to get into the clinic. The transatlantic outfit's experimental medicines...
endpts.com
May 27, 2025 at 11:50 AM
Investors pump $130M into protein degrader startup GlycoEra
endpts.com/investors-pu...
endpts.com/investors-pu...
Merus’ $MRUS Phase 2 overall survival data reach ‘home run’ scenario with their EGFR/LGR5 bispecific petosemtamab.
endpts.com/asco25-merus...
endpts.com/asco25-merus...
Merus’ Phase 2 overall survival data reach ‘home run’ scenario — analyst
Merus completed its rollout of Phase 2 head and neck cancer data on Thursday, touting overall survival results that at least one analyst said amount to a best-case outcome. ...
endpts.com
May 23, 2025 at 11:31 AM
Merus’ $MRUS Phase 2 overall survival data reach ‘home run’ scenario with their EGFR/LGR5 bispecific petosemtamab.
endpts.com/asco25-merus...
endpts.com/asco25-merus...
Altos Labs buys anti-aging startup Dorian Therapeutics for their "senoblockers".
endpts.com/altos-labs-b...
endpts.com/altos-labs-b...
Altos Labs buys anti-aging startup Dorian Therapeutics
Altos, led by industry stalwarts Hal Barron and Hans Bishop, brought Dorian Therapeutics into its fold this week, according to LinkedIn posts from the nimble company's co-founders.
endpts.com
May 21, 2025 at 2:02 PM
Altos Labs buys anti-aging startup Dorian Therapeutics for their "senoblockers".
endpts.com/altos-labs-b...
endpts.com/altos-labs-b...
Orionis Biosciences (private) Announces Strategic Partnership with Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer - $105M upfront, $2bn potential.
orionisbio.com/2025/05/gene...
orionisbio.com/2025/05/gene...
Orionis Biosciences Announces Strategic Partnership with Genentech to Discover and DevelopMolecular Glue Class Medicines for Cancer - Orionis Biosciences
Orionis Biosciences has announced a second collaboration with Genentech, worth $105 million upfront and up to $2 billion in potential milestone payments, to develop small-molecule glue medicines for o...
orionisbio.com
May 21, 2025 at 12:49 PM
Orionis Biosciences (private) Announces Strategic Partnership with Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer - $105M upfront, $2bn potential.
orionisbio.com/2025/05/gene...
orionisbio.com/2025/05/gene...
It'll be great to see everyone in Bruges and discuss some of the amazing progress that Haya Therapeutics is making in the pipeline and platform for finding, validating & drugging chronic disease state reversing targets in the regulatory genome! #BioEquity🧬 ❤️ 🫁 🦀
May 7, 2025 at 12:16 PM
It'll be great to see everyone in Bruges and discuss some of the amazing progress that Haya Therapeutics is making in the pipeline and platform for finding, validating & drugging chronic disease state reversing targets in the regulatory genome! #BioEquity🧬 ❤️ 🫁 🦀
Octagon shuts down after R&D challenges. Will be a trend in biotech in 2025.
www.fiercebiotech.com/biotech/octa...
www.fiercebiotech.com/biotech/octa...
Octagon shuts down after R&D challenges put it behind the 8 ball
Octagon Therapeutics has thrown in the towel. | Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after deprioritizing its lead program a...
www.fiercebiotech.com
April 30, 2025 at 7:56 PM
Octagon shuts down after R&D challenges. Will be a trend in biotech in 2025.
www.fiercebiotech.com/biotech/octa...
www.fiercebiotech.com/biotech/octa...
While on the subject of crowding (a talk given by AZ!), AstraZeneca Abandons Neuroscience, Prioritizes Weight Loss, Immunology. $XBI
www.biospace.com/business/ast...
www.biospace.com/business/ast...
AstraZeneca Abandons Neuroscience, Prioritizes Weight Loss, Immunology
Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro altogether.
www.biospace.com
April 30, 2025 at 11:15 AM
While on the subject of crowding (a talk given by AZ!), AstraZeneca Abandons Neuroscience, Prioritizes Weight Loss, Immunology. $XBI
www.biospace.com/business/ast...
www.biospace.com/business/ast...
Congrats to Haya Therapeutics CEO Samir Ounzain on being recognized as a top innovator on the Medicine Makers Power List. Just getting started! @HAYA_lncRNA themedicinemaker.com/awards/the-p...
April 30, 2025 at 9:10 AM
Congrats to Haya Therapeutics CEO Samir Ounzain on being recognized as a top innovator on the Medicine Makers Power List. Just getting started! @HAYA_lncRNA themedicinemaker.com/awards/the-p...
There is massive growth of "crowding" around the same targets in drug R&D over the last 20 years, with huge competition for every pharma/biotech & reduction in cost of entry via Chinese molecules. Novel targets are becoming everything for biotech to compete! $XBI (Aradhana - AZ)
April 30, 2025 at 8:23 AM
There is massive growth of "crowding" around the same targets in drug R&D over the last 20 years, with huge competition for every pharma/biotech & reduction in cost of entry via Chinese molecules. Novel targets are becoming everything for biotech to compete! $XBI (Aradhana - AZ)
Eli Lilly pens Creyon Bio AI oligonucleotide pact with $1B in biobucks on the table
www.fiercebiotech.com/biotech/eli-...
www.fiercebiotech.com/biotech/eli-...
Eli Lilly pens Creyon Bio AI oligonucleotide pact with $1B in biobucks on the table
Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed oligonucleotide therapies from Creyon Bio. | Eli Lilly is paying $13 mill...
www.fiercebiotech.com
April 30, 2025 at 5:57 AM
Eli Lilly pens Creyon Bio AI oligonucleotide pact with $1B in biobucks on the table
www.fiercebiotech.com/biotech/eli-...
www.fiercebiotech.com/biotech/eli-...
Caribou lays off 32% of staff & cuts lupus cell therapy program. “It is simply a reflection that we live in a moment where we have to do a small number of things incredibly well” - CEO Rachel Haurwitz. Good honesty in the toughest ever time for biotech.
endpts.com/caribou-lays...
endpts.com/caribou-lays...
Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient
Caribou Biosciences is paring down its pipeline and cutting about a third of its workforce as cell and gene therapy companies continue to struggle amid a bleak biotech market.
endpts.com
April 25, 2025 at 12:54 PM
Caribou lays off 32% of staff & cuts lupus cell therapy program. “It is simply a reflection that we live in a moment where we have to do a small number of things incredibly well” - CEO Rachel Haurwitz. Good honesty in the toughest ever time for biotech.
endpts.com/caribou-lays...
endpts.com/caribou-lays...
Reposted by Rich Law
Steve Usdin writing in BioCentury: “It’s official: FDA says its cuts are delaying drug regulation — Layoffs, lack of access to journals slow response FDA says”
April 25, 2025 at 11:07 AM
Steve Usdin writing in BioCentury: “It’s official: FDA says its cuts are delaying drug regulation — Layoffs, lack of access to journals slow response FDA says”
Haya Therapeutics
www.nature.com/articles/d43...
www.nature.com/articles/d43...
Reprogramming the software of the cell to fight disease
HAYA Therapeutics is using its unparalleled regulatory genome atlas and innovative proprietary platform to identify novel long non-coding RNAs and develop drug candidates that return diseased cells ba...
www.nature.com
April 25, 2025 at 9:44 AM
Haya Therapeutics
www.nature.com/articles/d43...
www.nature.com/articles/d43...
Reposted by Rich Law
New: We analyzed Trump's meme coin -
At least 27 crypto wallets have picked up $100 million worth of $TRUMP coins since his team said the top holders would join him for an "intimate private dinner."
Huge profit for Trump; "the most brazenly corrupt thing a President has ever done"
wapo.st/4iAatO1
At least 27 crypto wallets have picked up $100 million worth of $TRUMP coins since his team said the top holders would join him for an "intimate private dinner."
Huge profit for Trump; "the most brazenly corrupt thing a President has ever done"
wapo.st/4iAatO1
How Trump team turned a dinner invite into a crypto boon worth millions
iNearly two dozen crypto wallets acquired more than 100,000 $TRUMP meme coins, worth roughly $100 million, after the team said top buyers could join the president for dinner.
www.washingtonpost.com
April 24, 2025 at 10:25 PM
New: We analyzed Trump's meme coin -
At least 27 crypto wallets have picked up $100 million worth of $TRUMP coins since his team said the top holders would join him for an "intimate private dinner."
Huge profit for Trump; "the most brazenly corrupt thing a President has ever done"
wapo.st/4iAatO1
At least 27 crypto wallets have picked up $100 million worth of $TRUMP coins since his team said the top holders would join him for an "intimate private dinner."
Huge profit for Trump; "the most brazenly corrupt thing a President has ever done"
wapo.st/4iAatO1